Anne Clem Whitaker net worth and biography

Anne Whitaker Biography and Net Worth

Director of Icon

Ms. Anne Whitaker was appointed as a Non-Executive Director of ICON plc in July 2024.

Ms. Whitaker is a highly experienced life sciences executive with more than 30 years of leadership across global pharmaceutical, biotechnology, and specialty pharmaceutical companies. Ms. Whitaker has served as Chief Executive Officer of three clinical-stage biotechnology companies- Aerami Therapeutics, Synta Pharmaceuticals, and Novoclem Therapeutic; and brings deep operational and commercial expertise from senior executive and C-suite roles at Bausch Health, Sanofi, and GSK. During her tenure at Sanofi, she served as President of the North American Region, with full responsibility for commercial operations across the region. Earlier in her career, she held senior commercial leadership roles at GSK, spanning both U.S. and global responsibilities.

Ms. Whitaker currently serves as Chair of QurAlis, Operating Partner at New Vale Capital, interim Chair of Beaconcure Technologies and as a non-executive director of Trinity Life Sciences, Bespak, and Basilea Pharmaceuticals. She is also a Member of the Board of Trustees of the University of North Alabama. Her prior board experience includes Curio Digital Therapeutics, Ergomed plc, UDG Healthcare, Wolfspeed (formerly Cree), Mallinckrodt, KNOW Bio, Novoclem Therapeutics, Vectura Group, Synta Pharmaceuticals, OraSure Technologies, Bryn Pharma, Pulmatide Therapeutics, Nykode Therapeutics, Salix, Dendreon, Faron Pharmaceuticals, and Telix Pharmaceuticals. Ms. Whitaker holds a Bachelor of Science in Chemistry and Business from the University of North Alabama.

What is Anne Clem Whitaker's net worth?: The estimated net worth of Anne Clem Whitaker is at least $150.65 thousand as of August 11th, 2026. Whitaker owns 891 shares of Icon stock worth more than $150,649 as of August 17th. This net worth evaluation does not reflect any other investments that Whitaker may own. Learn More about Anne Clem Whitaker's net worth.
How do I contact Anne Clem Whitaker?: The corporate mailing address for Whitaker and other Icon executives is SOUTH COUNTY BUSINESS PARK LEOPARDSTOWN, DUBLIN L2, 00000. Icon can also be reached via phone at (531) 291-2000. Learn More on Anne Clem Whitaker's contact information.
Has Anne Clem Whitaker been buying or selling shares of Icon?: During the past quarter, Anne Clem Whitaker has sold $138,167.89 of Icon stock. Most recently, Anne Clem Whitaker sold 841 shares of the business's stock in a transaction on Tuesday, August 11th. The shares were sold at an average price of $164.29, for a transaction totalling $138,167.89. Following the completion of the sale, the director now directly owns 891 shares of the company's stock, valued at $146,382.39. Learn More on Anne Clem Whitaker's trading history.
Who are Icon's active insiders?: Icon's insider roster includes Barry Balfe (CEO), Brennan Brendan (CFO), John Climax (Director), Ciaran Murray (Director), and Anne Whitaker (Director). Learn More on Icon's active insiders.
Are insiders buying or selling shares of Icon?: In the last year, insiders at the medical research company sold shares 8 times. They sold a total of 9,531 shares worth more than $1,565,763.95. The most recent insider tranaction occured on August, 11th when Director Linda Grais sold 841 shares worth more than $138,167.89. Insiders at Icon own 44.0% of the company. Learn More about insider trades at Icon.
Information on this page was last updated on 8/11/2026.

Anne Clem Whitaker Insider Trading History at Icon

Transaction Date	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction	Details
8/11/2026	Sell	841	$164.29	$138,167.89	891

Anne Clem Whitaker Buying and Selling Activity at Icon

Icon Company Overview

ICON Public Limited Company, a clinical research organization, provides outsourced development and commercialization services in Ireland, rest of Europe, the United States, and internationally. The company specializes in the strategic development, management, and analysis of programs that support various stages of the clinical development process from compound selection to Phase I-IV clinical studies. It also offers clinical development services, including all phases of development, peri and post approval, data solutions, and site and patient access services; clinical trial management, consulting, and contract staffing services; and commercial services comprising clinical development strategy, planning and trial design, full study execution, and post-market commercialization. In addition, the company provides laboratory services, including bionanalytical, biomarker, vaccine, good manufacturing practice, and central laboratory services, as well as full-service and functional service partnerships to customers. Further, it offers adaptive trials, cardiac safety solutions, clinical and scientific operations, consulting and advisory, commercial positioning, decentralized and hybrid clinical trials, early clinical, laboratories, language services, medical imaging, real world intelligence, site and patient, and strategic solutions. The company serves pharmaceutical, biotechnology, and medical device industries, as well as government and public health organizations. ICON Public Limited Company was incorporated in 1990 and is headquartered in Dublin, Ireland.

Today's Range

Now: $168.68

$161.16

$169.37

50 Day Range

MA: $162.50

$140.73

$180.24

2 Week Range

Now: $168.68

$66.57

$203.91

Volume

235,320 shs

Average Volume

1,364,755 shs

Market Capitalization

$12.92 billion

P/E Ratio

39.60

Dividend Yield

N/A

Beta

1.21